In War for Amylin Pharmaceuticals, Inc., Icahn and Eastbourne Win a Battle: “Poison Pill” Revoked

BNET -- Carl Icahn and Eastbourne Capital seem to have won a small battle in their war for Amylin. The company’s board has decided not to commit financial suicide in the face of their insurgent board election bid.